DrugPatentWatch Database Preview
Erdafitinib - Generic Drug Details
Try a free trial
See Plans and Pricing
What are the generic sources for erdafitinib and what is the scope of erdafitinib freedom to operate?
Erdafitinib
is the generic ingredient in one branded drug marketed by Janssen Biotech and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Erdafitinib has seventy-seven patent family members in thirty-seven countries.
One supplier is listed for this compound.
Summary for erdafitinib
| International Patents: | 77 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 29 |
| Clinical Trials: | 12 |
| Patent Applications: | 24 |
| DailyMed Link: | erdafitinib at DailyMed |
Synonyms for erdafitinib
| 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)- |
| 1346242-81-6 |
| 5SF |
| 890E37NHMV |
| AC-30222 |
| AK547250 |
| AS-35040 |
| BCP20346 |
| CHEMBL3545376 |
| compound 4 [WO2011135376] |
| CS-4988 |
| D10927 |
| DB12147 |
| Erdafitinib (JNJ-42756493) |
| Erdafitinib (USAN/INN) |
| Erdafitinib [USAN:INN] |
| Erdafitinib,JNJ-42756493 ,JNJ 42756493 ,JNJ42756493 |
| Erdafitinib; JNJ-42756493 |
| EX-A2564 |
| GTPL9039 |
| HY-18708 |
| JNJ 42756493 |
| JNJ-42756493 |
| JNJ-42756493 (Erdafitinib) |
| jnj-42756493-erdafitinib |
| JNJ42756493 |
| MFCD28502040 |
| N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
| N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine |
| s8401 |
| SB16854 |
| SCHEMBL2583760 |
| UNII-890E37NHMV |
| ZINC168520308 |
US Patents and Regulatory Information for erdafitinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
